Product Description
GLPG0259 is a small-molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), a kinase enzyme that plays a role in important inflammatory pathways. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22950522/)
Mechanisms of Action: MAPK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galapagos
Company Location: 2800 MECHELEN C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2009-015898-12 | P2 |
Completed |
Arthritis, Rheumatoid |
2012-03-10 |
|
| GLPG0259-CL-201 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-04-01 |
|
| GLPG0259-CL-104 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
|
| GLPG0259-CL-103 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |